Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspirin to be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3200

    Menu

    DSSTox_CID_3200

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dr. Reddy's Laboratories

              Contact Supplier
              • Development Update
              Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market

              Details:

              The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.

              Lead Product(s): Lansoprazole

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 22, 2021

              Dr Reddy Company Banner

              CPhI North America

              Attending

              envelop Contact Supplier

              NHS England

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aspirin to be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer

              Details:

              Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.

              Lead Product(s): Aspirin,Avelumab,Lansoprazole

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: University of Manchester

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY